Printer Friendly

CAMBRIDGE BIOTECH RESTRUCTURES DIAGNOSTICS BUSINESS INTO TWO DIVISIONS; APPOINTS EXECUTIVE VP/GM AMERICAS/FAR EAST UNIT

CAMBRIDGE BIOTECH RESTRUCTURES DIAGNOSTICS BUSINESS INTO TWO DIVISIONS;
 APPOINTS EXECUTIVE VP/GM AMERICAS/FAR EAST UNIT
 WORCESTER, Mass., Feb. 5 /PRNewswire/ -- Cambridge Biotech Corporation (NASDAQ: CBCX) today announced a restructuring of its diagnostics business into two geographic entities. The Americas/Far East Diagnostics Division will cover Canada, the United States, the rest of the Americas, and the Far East; the European Diagnostics Division will cover Europe, the Middle East, and Africa. The company also announced the appointment of Stephen D. Hayter to the newly-created position of the executive vice president-general manager of its Americas/Far East Diagnostics Division.
 Dr. Anthony C. Nicholls, previously executive vice president of sales and marketing, has been appointed to the new position, executive vice president-general manager, European Diagnostics Division. He now assumes responsibility for all of the company's diagnostics activity in the European division, including CBC Limited, the company's manufacturing facility in Ireland, formerly Noctech Limited.
 The growth of the company's diagnostics portfolio over the past year called for the regionalization of its diagnostics business and the creation of the new positions, according to Dr. Patrick J. Leonard, President and CEO of Cambridge Biotech. Hayter will report to Dr. Leonard in his new position, as will Dr. Nicholls. Dr. Leonard will continue to head Cambridge's Biopharmaceuticals Division.
 From 1987 to December of 1991, Hayter was president and chief executive officer of ADI Diagnostics Inc., a diagnostics company focused on infectious diseases. Prior to that, he spent 15 years at Abbott Laboratories, his last position being executive vice president and representative director of Dainabot kk of Osaka, Japan, a joint venture between Abbott Laboratories and Dainippon Pharmaceuticals. For the six years previous, he served as director of Abbott's Canadian Diagnostics Division, and for the six years prior to that, held regional manager and sales positions with the Abbott Diagnostic Division.
 Commenting on the appointment, Dr. Leonard said, "We welcome Mr. Hayter to our staff. His extensive experience in diagnostics will make a significant contribution to the future of our business, and his experience will be of vital importance as we seek to improve our worldwide market share."
 Dr. Anthony C. Nicholls, who will oversee the European Diagnostics Division, was formerly the president of Biotech Research Laboratories, Inc. from May 1990 until September 1990. At that time, Biotech Research merged with the former Cambridge BioScience Corporation, creating Cambridge Biotech. Prior to that, he had been executive vice president at Biotech Research since August 1989, and from May 1988 to August 1989 he was vice president-general manager of the Bioanalytical Division of Fisher Scientific.
 Cambridge Biotech Corporation is a leader in the development of recombinant technology and a major producer of viral diagnostic screening and confirmatory products. The company utilizes recombinant technology in the development and production of antigens. The company also develops adjuvants and monoclonal antibodies as the basis for diagnostic, vaccine and therapeutic products for humans and animals.
 -0- 2/5/92
 /CONTACT: Peter P. Hartman, vice president-finance and chief financial officer of Cambridge Biotech, 508-797-5777, or Mark Cohen of Cameron Associates, 212-644-9560, for Cambridge Biotech/
 (CBCX) CO: Cambridge Biotech Corporation ST: Massachusetts IN: MTC SU: RCN


PS-AH -- NY002 -- 7011 02/05/92 08:31 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 5, 1992
Words:530
Previous Article:DEPRENYL RESEARCH LIMITED REPORTS EARNINGS
Next Article:CRI LIQUIDATING REIT EXPECTS TO DISTRIBUTE MORTGAGE PROCEEDS IN TWO PAYMENTS
Topics:


Related Articles
IMCERA'S PITMAN-MOORE UNIT AND CAMBRIDGE BIOTECH ANNOUNCE A DEFINITIVE MASTER AGREEMENT IN ANIMAL HEALTH FIELD
CAMBRIDGE BIOTECH GRANTS SUBLICENSE TO GENENTECH FOR DEVELOPMENT OF AIDS VACCINE
MILES DIAGNOSTICS RESTRUCTURES TO CREATE STRATEGIC BUSINESS UNITS
CAMBRIDGE BIOTECH AND GULL LABORATORIES ENTER MANUFACTURING/DISTRIBUTION AGREEMENT
C O R R E C T I O N TO CAMBRIDGE BIOTECH CORPORATION ACQUIRES MINORITY STAKE IN ADI.
CAMBRIDGE BIOTECH CORPORATION TO CONSOLIDATE U.S. MANUFACTURING OPERATIONS; EXPAND OPERATIONS IN IRELAND
CAMBRIDGE BIOTECH REPORTS 1992 RESULTS
CAMBRIDGE BIOTECH CORPORATION ANNOUNCES SECOND QUARTER RESULTS
CAMBRIDGE BIOTECH CORPORATION ANNOUNCES MANAGEMENT APPOINTMENTS
CAMBRIDGE BIOTECH SIGNS AGREEMENT WITH BIOMERIEUX TO SELL ITS RETROVIRAL DIAGNOSTIC BUSINESS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters